Understand the source comparison
TB-4 Dosing: Wound Type Comparison
Superficial abrasion or laceration (<2cm depth) 2mg subcutaneous Twice weekly × 2–3 weeks 50% closure by day 7; complete epithelialisation by day 14–18 Standard protocol. Most cost-effective for minor injuries with high success rate Deep tissue injury or surgi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Superficial abrasion or laceration (<2cm depth)
- 2mg subcutaneous
- Twice weekly × 2–3 weeks
- 50% closure by day 7; complete epithelialisation by day 14–18
- Standard protocol. Most cost-effective for minor injuries with high success rate
- Deep tissue injury or surgical incision (>2cm depth)
- Twice weekly × 4–6 weeks
- Visible granulation tissue by day 10; functional closure by week 4–6
- Requires extended duration to support full dermal remodelling. Do not stop at surface closure
- Chronic non-healing wound (diabetic ulcer, pressure sore)
- 2–4mg subcutaneous
- 3× weekly × 6–8 weeks
- Marginal improvement by week 2; measurable reduction by week 4
- Higher dose and frequency required due to impaired baseline angiogenesis. Combine with vascular support
- Tendon or ligament strain
- 2mg subcutaneous or localized injection
- Twice weekly × 6–8 weeks
- Reduced pain/inflammation by week 2; structural repair visible on imaging by week 6+
- TB-4 promotes collagen alignment. Pair with controlled load progression for optimal outcomes